Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

BACKGROUND: Nivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2. To further improve the therapeutic efficacy of first-line therapy, exploration of a nivolumab-chemotherapy combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Boku, N, Ryu, M -H, Kato, K, Chung, H C, Minashi, K, Lee, K -W, Cho, H, Kang, W K, Komatsu, Y, Tsuda, M, Yamaguchi, K, Hara, H, Fumita, S, Azuma, M, Chen, L -T, Kang, Y -K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386029/
https://www.ncbi.nlm.nih.gov/pubmed/30566590
http://dx.doi.org/10.1093/annonc/mdy540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386029/
https://www.ncbi.nlm.nih.gov/pubmed/30566590
http://dx.doi.org/10.1093/annonc/mdy540

Ejemplares similares